Literature DB >> 16998483

Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.

Daniela S Krause1, Katherine Lazarides, Ulrich H von Andrian, Richard A Van Etten.   

Abstract

In individuals with chronic myeloid leukemia (CML) treated by autologous hematopoietic stem cell (HSC) transplantation, malignant progenitors in the graft contribute to leukemic relapse, but the mechanisms of homing and engraftment of leukemic CML stem cells are unknown. Here we show that CD44 expression is increased on mouse stem-progenitor cells expressing BCR-ABL and that CD44 contributes functional E-selectin ligands. In a mouse retroviral transplantation model of CML, BCR-ABL1-transduced progenitors from CD44-mutant donors are defective in homing to recipient marrow, resulting in decreased engraftment and impaired induction of CML-like myeloproliferative disease. By contrast, CD44-deficient stem cells transduced with empty retrovirus engraft as efficiently as do wild-type HSCs. CD44 is dispensable for induction of acute B-lymphoblastic leukemia by BCR-ABL, indicating that CD44 is specifically required on leukemic cells that initiate CML. The requirement for donor CD44 is bypassed by direct intrafemoral injection of BCR-ABL1-transduced CD44-deficient stem cells or by coexpression of human CD44. Antibody to CD44 attenuates induction of CML-like leukemia in recipients. These results show that BCR-ABL-expressing leukemic stem cells depend to a greater extent on CD44 for homing and engraftment than do normal HSCs, and argue that CD44 blockade may be beneficial in autologous transplantation in CML.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16998483     DOI: 10.1038/nm1489

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  152 in total

Review 1.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 2.  Plasticity and maintenance of hematopoietic stem cells during development.

Authors:  Suman Kanji; Vincent J Pompili; Hiranmoy Das
Journal:  Recent Pat Biotechnol       Date:  2011-04

3.  Bone marrow homing and engraftment of human hematopoietic stem and progenitor cells is mediated by a polarized membrane domain.

Authors:  Andre Larochelle; Jennifer M Gillette; Ronan Desmond; Brian Ichwan; Amy Cantilena; Alexandra Cerf; A John Barrett; Alan S Wayne; Jennifer Lippincott-Schwartz; Cynthia E Dunbar
Journal:  Blood       Date:  2012-01-06       Impact factor: 22.113

4.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

Review 5.  The cancer stem cell paradigm: a new understanding of tumor development and treatment.

Authors:  Johnathan D Ebben; Daniel M Treisman; Michael Zorniak; Raman G Kutty; Paul A Clark; John S Kuo
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

6.  Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia.

Authors:  Benjamin J Frisch; John M Ashton; Lianping Xing; Michael W Becker; Craig T Jordan; Laura M Calvi
Journal:  Blood       Date:  2011-09-28       Impact factor: 22.113

7.  Expression of BCR/ABL p210 from a knockin allele enhances bone marrow engraftment without inducing neoplasia.

Authors:  Samantha B Foley; Zacariah L Hildenbrand; Abigail A Soyombo; Jeffery A Magee; Yipin Wu; Katherine I Oravecz-Wilson; Theodora S Ross
Journal:  Cell Rep       Date:  2013-10-03       Impact factor: 9.423

8.  Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities.

Authors:  Bryan P Toole
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

9.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

Review 10.  Right on target: eradicating leukemic stem cells.

Authors:  Daniela S Krause; Richard A Van Etten
Journal:  Trends Mol Med       Date:  2007-11-05       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.